arrow
S

Sean Ewings

southampton clinical trials unit
H指数:24
被引数:2,118

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Assessing a facilitated social network intervention for health outcomes in lonely and socially isolated people: the pragmatic; cluster-randomized PALS trial

评估一项促进性社交网络干预措施对孤独及社会孤立人群健康结局的影响:一项实用性、整群随机PALS试验

2026-04-030
OAAI
Self-help cognitive behavioural therapy for hot flushes and night sweats during androgen deprivation therapy for prostate cancer: the MANCAN2 randomized controlled trial

前列腺癌雄激素剥夺治疗期间针对潮热和盗汗的自助认知行为疗法:MANCAN2随机对照试验

2026-03-240
OAAI
Real world implementation of AlcoChange, a smartphone digital therapeutic to improve outcomes from alcohol-related liver disease: protocol for an individually randomised parallel group controlled trial
2025-10-310
OA
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial

结构性炎症和上皮间质转化决定了对nivolumab的敏感性: 一项安慰剂对照的随机III期试验

2025-07-210
OA
HARE-40: A phase I/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma

HARE-40:一项针对HPV16驱动性癌患者治疗性HPV疫苗(BNT113)的Ⅰ/Ⅱ期临床试验

2024-09-011
PRE
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
2023-02-0161
OAAI
Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
2022-03-1015
OAAI
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2
2021-11-1314
OAAI
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
2021-08-2783
OAAI